The Motley Fool
01 Aug 2026, 17:57 UTC · 2h ago
XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
01 Aug 2026, 17:57 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The Invesco Biotechnology & Genome ETF (PBE) is outperforming the State Street Health Care Select Sector SPDR ETF (XLV) year-to-date, with returns of 10.2% compared to 3.4%. — Strong relative performance in a specialized biotech fund suggests a shift in investor appetite toward high-growth genomics over broad healthcare stability.
+0.40Small-cap stocks are currently experiencing their strongest year since 1991, driving the performance of the PBE ETF which holds 52% of its assets in small caps. — A multi-decade high in small-cap performance indicates a significant rotation in risk appetite that could affect broader market indices.
+0.30The State Street Health Care ETF (XLV) maintains a significantly lower expense ratio of 0.08% compared to the Invesco fund's 0.58%. — Lower fees are a long-term positive for total returns but have minimal immediate impact on daily price movements.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Mentioned only as a top holding in an ETF with a slight price gain.
Mentioned only as a top holding in an ETF with a slight price dip.
Mentioned only as a top holding in an ETF with a slight price dip.
Mentioned only as a top holding in an ETF with a slight price dip.
Mentioned only as a top holding in an ETF with a slight price dip.
Mentioned only as a top holding in an ETF with a slight price dip.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
24/7 Wall Street
17h ago
